Last reviewed · How we verify
NCT03192631
Financial Incentives to Improve Acceptance of Antipsychotic Injections
NA trial testing Financial incentive in Schizophrenia in 20 participants. Status unknown.
31 December 2019
Quick facts
| Lead sponsor | Focus Community Mental Health Team |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 20 |
| Start date | 1 July 2017 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2021 |
Drugs / interventions tested
- Financial incentive
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
- Schizo Affective Disorder — all drugs for Schizo Affective Disorder →
- Bipolar I Disorder — all drugs for Bipolar I Disorder →
Sponsor
Focus Community Mental Health Team
Who can join
Adults 18 to 65, any sex, with Schizophrenia or Schizo Affective Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
There is a lack of incentive approach for patients who suffer from schizophrenia yet lack the insight to accept treatment. Most existing approaches involve coercion and involuntary hospitalizations. This study will explore whether patients with poor insight and lacking in competence for treatment decisions will improve their acceptance and adherence of depot injection antipsychotic medication if a financial incentive is offered. Ethical considerations are also explored for this innovative pilot study
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03192631
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Financial incentive
Trials testing the same drug.
- NCT07071753 — Optimizing Online Purchasing of Fruits, Vegetables, and Legumes for Low-Income Families · NA · not yet recruiting
- NCT05586308 — Incentive-based and Media Literacy Informed Approaches to Improve Vaping Cessation · NA · completed
- NCT05012163 — Lottery Incentive Nudges to Increase Influenza Vaccinations · NA · completed
- NCT04285905 — Male Partner-assisted Contact Tracing for HIV and Tuberculosis in Malawi · Phase 2, PHASE3 · terminated
- NCT03244189 — Prevention of Urinary Stones With Hydration · NA · completed
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03192631 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Focus Community Mental Health Team
- Last refreshed: 20 June 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03192631.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing